Open an account

Novelstem International

NSTM · OTC

$0.0095+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About NSTM

NovelStem International Corp. develops novel diagnostic technology that can predict patients resistance to chemotherapy allowing for cancer treatments and the potential to reduce resistance to chemotherapy. The company is headquartered in Boca Raton, Florida. The firm's primary assets are NewStem Ltd (NewStem) and NetCo Partners (NetCo). NewStem focuses on the development and commercialization of diagnostic technology that can predict patients’ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is principally focused on utilizing proprietary human Pluripotent Stem Cells (hPSCs) and Haploid human Pluripotent Stem Cells (HhPSCs) in the development of diagnostic and therapeutic products in oncology. Its NewStem Software Diagnostic Device (NSDD) is a bioinformatics-based software medical device platform that provides oncologists with information regarding the presence of mutations in tumors, which may confer patient resistance to certain anti-cancer drugs. NetCo is a media business interest which owns Net Force, a book publishing franchise.

Employees
0
Headquarters
Boca Raton, Florida
Listed
Nov 12, 1993
Sector
Health Care
Industry
Biotechnology
Website
novelstem.com

NSTM key statistics

Market cap
468.66K
Price-earnings ratio
0.20
Dividend yield
—
Average volume
39.43K
Volume
11.94K
Open price
$0.0095
High today
$0.0095
Low today
$0.0095
52 Week high
$0.0357
52 Week low
$0.0062

Novelstem International (NSTM) at a glance

As of Oct 7, 2026, Novelstem International (NSTM) shares are priced at $0.0095, giving the company a market cap of 468.66K and a price-to-earnings ratio of 0.20.

Volume so far is 11.94K shares, below the average of 39.43K shares a day.

Over the past year Novelstem International has ranged from $0.0062 to $0.0357, and now sits 11% of the way up that range.

Novelstem International met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q3 FY25 it reported $0.00 per share against an estimate of $0.00.

NSTM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 42.8% on average.

  1. Q3 FY07: reported -$0.06 per share against an estimate of -$0.0544
  2. Q4 FY07: reported -$0.07 per share against an estimate of -$0.0459
  3. Q1 FY08: reported -$0.10 per share against an estimate of -$0.0816
  4. Q2 FY08: reported -$0.06 per share against an estimate of -$0.0816
  5. Q3 FY08: reported -$0.06 per share against an estimate of -$0.0612
  6. Q1 FY09: reported $0.00 per share against an estimate of -$0.0714
  7. Q2 FY09: reported -$0.16 per share against an estimate of -$0.0204
  8. Q3 FY25: reported $0.00 per share against an estimate of $0.00

Similar companies

Companies in the same industry as Novelstem International

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.